The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.
 
Aditya Juloori
Consulting or Advisory Role - AquaLung Therapeutics; General Electric; Isoray
Research Funding - AstraZeneca
 
Gregory Gan
Honoraria - AstraZeneca
Consulting or Advisory Role - IDEO Oncology
Research Funding - Aclaris Therapeutics
Patents, Royalties, Other Intellectual Property - US Patent Application #: 15/506,421 Title: Inhibition of MK2 in Treatment of Cancer Co-inventor: Gregory Gan, Ellen Beswick Patent filed on Dec 2015
 
Jun Zhang
No Relationships to Disclose
 
Mohamed E. Abazeed
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Bayer
Patents, Royalties, Other Intellectual Property - Methods and Systems for Massively Parallel Phenotyping of Gene Variants
Travel, Accommodations, Expenses - Siemens Healthineers
 
Jared H Hara
No Relationships to Disclose
 
Andrew Baschnagel
No Relationships to Disclose
 
Anne M. Traynor
No Relationships to Disclose
 
Michael F. Bassetti
No Relationships to Disclose
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Blueprint Pharmaceutic; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; MSD Oncology; Novartis; Pfizer; Regeneron; Roche; Sanofi/Aventis; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; AstraZeneca; Genentech; Lilly; Takeda Science Foundation
Research Funding - Bristol-Myers Squibb (Inst)
 
Steven J. Chmura
Employment - Astellas Pharma (I); Takeda (I)
Honoraria - Reflexion Medical
Consulting or Advisory Role - AstraZeneca; Genentech
Research Funding - AstraZeneca/MedImmune; BMS; Merck
Patents, Royalties, Other Intellectual Property - UptoDate article
 
Christine M. Bestvina
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Bristol-Myers Squibb/Celgene; Creative Educational Concepts; Curio Science; CVS; Genentech; Janssen; Jazz Pharmaceuticals; Novartis; Novocure; OncLive Clinical Congress Consultants; Sanofi/Regeneron; Seagen; Takeda
Speakers' Bureau - Merck
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb